Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

GXP-1 is under development for the treatment of psoriasis, rheumatoid arthritis, inflammation of the colon, stroke, premature labor (tocolysis) and transplantation rejection. It is administered ...

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...